Vaxxa reports increased revenue in the fourth quarter compared with the same period the year before. The operating loss increased.Revenue rose 36.3 percent to SEK 22.9 million (16.8).The EBITDA result was SEK -0.8 million (-0.5). The operating result was SEK -1.2 million (-0.6). The result after tax was SEK -1.4 million (-0.6). Earnings per share amounted to SEK -0.032 (-0.016). Cash and cash equivalents amounted to SEK 7.6 million (10.2)."The result for the fourth quarter is significantly weaker than what was communicated in earlier forecasts. This is mainly due to year-end appropriations and conservative measures carried out in connection with the annual closing," says CEO Karl Frindberg. "During the quarter, all identified doubtful trade receivables were written down, inventory was adjusted to estimated realizable value, and personnel costs and other accruals were corrected. The measures are largely one-off in nature and aim to clean up the balance sheet and income statement ahead of the next growth phase, rather than reflect the ongoing business's earnings capacity." Vaxxa, SEK millionQ4-2025Q4-2024ChangeNet sales22.916.836.3%EBITDA-0.8-0.5Operating result-1.2-0.6Net income-1.4-0.6Earnings per share, SEK-0.032-0.016Cash and cash equivalents7.610.2-25.5%